Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer

References

• Hundal R, Shaffer EA, Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–12. doi:10.2147/CLEP.S37357.
   PubMed Web of Science ®Google Scholar
• Wang YF. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20(14):4085–4092. doi:10.3748/wjg.v20.i14.4085.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23(22):3978–3998. doi:10.3748/wjg.v23.i22.3978.
   PubMed Web of Science ®Google Scholar
• Cui X, Zhu S, Tao Z, Deng X, Wang Y, Gao Y, Liao Y, Ma W, Zhang Y, Ma X, et al. Long-term outcomes and prognostic markers in gallbladder cancer. Med. 2018;97(28):e11396. doi:10.1097/MD.0000000000011396.
   PubMed Web of Science ®Google Scholar
• Zaidi MY, Maithel SK. Updates on Gallbladder Cancer management. Curr Oncol Rep. 2018;20(2):21. doi:10.1007/s11912-018-0664-3.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Jarnagin W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates Surg. 2019;71(2):217–225. doi:10.1007/s13304-019-00670-z.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Amedei A, Niccolai E, D’Elios MM, T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. Clin Dev Immunol. 2011;2011:320571. doi:10.1155/2011/320571.
   PubMedGoogle Scholar
• Blair AB, Murphy A. Immunotherapy as a treatment for biliary tract cancers: a review of approaches with an eye to the future. Curr Probl Cancer. 2018;42(1):49–58. doi:10.1016/j.currproblcancer.2017.10.004.
   PubMed Web of Science ®Google Scholar
• Fluxa P, Rojas-Sepúlveda D, Gleisner MA, Tittarelli A, Villegas P, Tapia L, Rivera MT, López MN, Catán F, Uribe M, et al. High CD8(+) and absence of Foxp3(+) T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival. Bmc Cancer. 2018;18(1):243. doi:10.1186/s12885-018-4147-6.
   PubMedGoogle Scholar
• Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, Schröder MS, Sreenivasamurthy SK, Kim S-W, Phalke S, et al. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat Commun. 2020;11(1):4225. doi:10.1038/s41467-020-17880-4.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi:10.1186/s12943-018-0864-3.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, Shen M, Ruan S, Wasan HS, Qiu S, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083. doi:10.1038/s41598-020-58674-4.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J-C, Shin DW, Kim J, Hwang J-H. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10(1):12348. doi:10.1038/s41598-020-69366-4.
   PubMed Web of Science ®Google Scholar
• Gou M, Zhang Y, Liu T, Si H, Wang Z, Yan H, Qian N, Dai G, PD-1 Inhibitors could improve the efficacy of chemotherapy as first-line treatment in biliary tract Cancers: a propensity score matching based analysis. Front Oncol. 2021;11:648068. doi:10.3389/fonc.2021.648068.
   PubMed Web of Science ®Google Scholar
• Tomita K, Takano K, Shimazu M, Okihara M, Sano T, Chiba N, Kawachi S. Long-term survival of a recurrent gallbladder carcinoma patient with lymph node and peritoneal metastases after multidisciplinary treatments: a case report. Surg Case Rep. 2016;2(1):12. doi:10.1186/s40792-016-0135-8.
   PubMedGoogle Scholar
• Kawamoto M, Wada Y, Koya N, Takami Y, Saitsu H, Ishizaki N, Tabata M, Onishi H, Nakamura M, Morisaki T, et al. Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report. Surg Case Rep. 2018;4(1):115. doi:10.1186/s40792-018-0512-6.
   PubMedGoogle Scholar
• Rao J, Xia J, Yang W, Wu C, Sha B, Zheng Q, Cheng F, Lu L. Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report. Ann Transl Med. 2020;8(23):1609. doi:10.21037/atm-20-4420.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Sci. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. The Lancet Haematology. 2020;7(11):e816–e826. doi:10.1016/S2352-3026(20)30277-5.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M, Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:1–13. doi:10.1155/2010/956304.
   Google Scholar
• Siegler EL, Wang P. Preclinical models in chimeric antigen receptor-engineered T cell therapy. Hum Gene Ther. 2018.
   PubMedGoogle Scholar
• Wen Z, Si A, Yang J, Yang P, Yang X, Liu H, Yan X, Li W, Zhang B. Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma. HPB (Oxford). 2017;19(11):951–956. doi:10.1016/j.hpb.2017.06.011.
   PubMed Web of Science ®Google Scholar
• Sinha SR, Prakash P, Singh RK, Sinha DK. Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer. World J Gastrointest Surg. 2022;14(11):1272–1284. doi:10.4240/wjgs.v14.i11.1272.
   PubMed Web of Science ®Google Scholar
• Sachan A, Saluja SS, Nekarakanti, PKN, Mahajan B, Nag HH, Mishra, PK. Raised CA19–9 and CEA have prognostic relevance in gallbladder carcinoma. Bmc Cancer. 2020;20(1):826. doi:10.1186/s12885-020-07334-x.
   PubMed Web of Science ®Google Scholar
• Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N, Junghans RP, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64(7):817–829. doi:10.1007/s00262-015-1692-6.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T, Shiku H, et al. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunol. 2016;5(9):e1211218. doi:10.1080/2162402X.2016.1211218.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Osborn M, Tolar J, Kim C. Incorporation of immune checkpoint blockade into chimeric antigen receptor t cells (CAR-Ts): combination or built-in CAR-T. IJMS. 2018;19(2):340. doi:10.3390/ijms19020340.
   Google Scholar
• Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al. Phase i escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–1258. doi:10.1016/j.ymthe.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases. Cancer Gene Ther. 2020;27(5):341–355. doi:10.1038/s41417-019-0104-z.
   PubMed Web of Science ®Google Scholar
• Tandon N. Generation of stable expression mammalian cell lines using lentivirus. Bio Protoc. 2018;8(21).
   PubMed Web of Science ®Google Scholar
• Swift S. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol, 2001. Chapter 10: p.Unit 10 17C.
   PubMedGoogle Scholar
• Carrasco C, Tittarelli A, Paillaleve N, Pozo MD, Rojas-Sepúlveda D, Barría O, Fluxá P, Hott M, Martin C, Quezada C, et al. The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6. CK17, And CD10 In Gallbladder-Cancer Patients. Diagn (Basel). 2021;11(2):153. doi:10.3390/diagnostics11020153.
   PubMedGoogle Scholar
• Bosslet K, Lüben G, Schwarz A, Hundt E, Harthus HP, Seiler FR, Muhrer C, Kayser K, Klöppel G, Sedlacek HH. Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA). Int J Cancer. 1985;36(1):75–84. doi:10.1002/ijc.2910360113.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011;129(12):2935–2944. doi:10.1002/ijc.25960.
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 + T cells. Oncoimmunol. 2012;1(4):458–466. doi:10.4161/onci.19855.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.4195.
   PubMed Web of Science ®Google Scholar
• Zolov SN, Rietberg SP, Bonifant CL. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy. 2018;20(10):1259–1266. doi:10.1016/j.jcyt.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Rojas-Sepulveda D, Tittarelli A, Gleisner MA, Ávalos I, Pereda C, Gallegos I, González FE, López MN, Butte JM, Roa JC, et al. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. Cancer Immunol Immunother. 2018;67(12):1897–1910. doi:10.1007/s00262-018-2157-5.
   PubMed Web of Science ®Google Scholar
• Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki I-M, Okazaki T, PD-1 primarily targets TCR signal in the inhibition of functional T cell activation. Front Immunol. 2019;10:630. doi:10.3389/fimmu.2019.00630.
   PubMed Web of Science ®Google Scholar
• Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102. doi:10.1186/s13045-018-0646-9.
   PubMed Web of Science ®Google Scholar
• Zhang BL, Li D, Gong Y-L, Huang Y, Qin D-Y, Jiang L, Liang X, Yang X, Gou H-F, Wang Y-S, et al. Preclinical evaluation of chimeric antigen receptor–modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther. 2019;30(4):402–412. doi:10.1089/hum.2018.229.
   PubMed Web of Science ®Google Scholar
• Cai X, Wei B, Li L, Chen X, Liu W, Cui J, Lin Y, Sun Y, Xu Q, Guo W, et al. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Int Immunopharmacol. 2020;88:106858. doi:10.1016/j.intimp.2020.106858.
   PubMed Web of Science ®Google Scholar
• Neyaz A, Husain N, Kumari S, Gupta S, Shukla S, Arshad S, Anand N, Chaturvedi A. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy. Histopathol. 2018;73(4):622–633. doi:10.1111/his.13669.
   PubMed Web of Science ®Google Scholar
• Lin J, Long J, Wan X, Chen J, Bai Y, Wang A, Yang X, Wu Y, Robson SC, Sang X, et al. Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression. Bmc Cancer. 2018;18(1):766. doi:10.1186/s12885-018-4651-8.
   PubMed Web of Science ®Google Scholar
• Cha SE, Kujawski M, J Yazaki P, Brown C, Shively JE. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunol. 2021;10(1):1899469. doi:10.1080/2162402X.2021.1899469.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt–Wolf IH, Hombach AA, Abken H. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterol. 2012;143(4):1095–107 e2. doi:10.1053/j.gastro.2012.06.037.
   PubMed Web of Science ®Google Scholar
• Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S, Dholaria B. CAR-T cell therapy in solid tumors: a review of current clinical trials. E J Haem. 2022;3(Suppl 1):24–31. doi:10.1002/jha2.356.
   Google Scholar
• Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE. Glioblastoma-targeted CD4+ CAR-T cells mediate superior antitumor activity. JCI Insight. 2018;3(10). doi:10.1172/jci.insight.99048.
   Web of Science ®Google Scholar
• Li T, Wu B, Yang T, Zhang L, Jin K. The outstanding antitumor capacity of CD4(+) T helper lymphocytes. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188439. doi:10.1016/j.bbcan.2020.188439.
   PubMed Web of Science ®Google Scholar
• Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaître F, Grandjean CL, Garcia Z, Bousso P. A cross-talk between CAR-T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6(57). doi:10.1126/sciimmunol.abd4344.
   PubMed Web of Science ®Google Scholar
• Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, Gao X, Li X, Zhang Y, Xu H, et al. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Med. 2019;8(10):4753–4765. doi:10.1002/cam4.2361.
   PubMed Web of Science ®Google Scholar
• Hombach A, Barden M, Hannappel L, Chmielewski M, Rappl G, Sachinidis A, Abken H. IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol Ther. 2022;30(2):593–605. doi:10.1016/j.ymthe.2021.10.011.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697–5706. doi:10.1158/0008-5472.CAN-11-0103.
   PubMed Web of Science ®Google Scholar